Exploring the Future of Stem Cell Bioprocessing with AI-Supported Quality Assurance

Have you ever wondered how AI is transforming the landscape of stem cell bioprocessing, making it more efficient and reliable than ever before??

In this interview, we had the opportunity to speak with DI Dr. Klaus Graumann , CEO and Co-Founder of Phoenestra GmbH , a leading expert in developing platform technologies for stem cell-derived products. Dr. Graumann has been at the forefront with over 20 years of experience in the biopharmaceutical industry.

Introduction to Klaus Graumann and Phoenestra

Klaus Graumann's journey from a lab head at Novartis to the CEO of Phoenestra is a remarkable story. He shares his passion for stem cell biology, which was ignited by the invention of iPSC technology over 15 years ago.

In the interview, we address various aspects of stem cell bioprocessing and also the use of AI-based image analysis tools such as IKOSA.

Here is a little glimpse into what we discussed:

?? Quality Control & Monitoring: Phoenestra uses a robust monitoring system, including pH, temperature, oxygen levels, and glucose measurements. Microscopy is vital for assessing cell morphology, and viability.

?? AI and Image Analysis: Dr. Graumann highlighted the integration of AI and image analysis through the IKOSA platform to automate quality control and enhance productivity. This approach helps to keep track of cell counts, cell morphology and maintain process reproducibility.

?? Early Detection with IKOSA: The interview discusses how implementing IKOSA aids in the early detection of process deviations, potentially saving costly batch failures in manufacturing.

?? Balancing Costs and Productivity: Dr. Graumann emphasized that tools like IKOSA contribute to maintaining a balance between costs, risks, and productivity in the bioprocessing workflow.

?? iPSCs vs. MSCs: The interview touches upon the contrasting nature of iPSCs, which are easier to expand, and MSCs, which require special handling due to their sensitivity.

?? Rapid Expansion: Dr. Graumann highlighted that iPSCs can be expanded significantly within four to five days, making them a promising candidate for regenerative medicine.

?? Exciting Developments: The future may hold universal iPSC libraries and the use of extracellular vesicles in therapies as they show immense potential.

?? Collaboration and Data Sharing: Dr. Graumann underlines the importance of collaboration and data sharing among companies in this field to advance research and development.

??? To read the full interview and delve deeper into the world of AI-supported quality assurance in stem cell bioprocessing, visit our website. Dr. Graumann shared some valuable insights, and we are sure you will find it rewarding to read. ????

The conversation sheds light on the advancements, challenges, and promising directions in stem cell bioprocessing and the potential of AI-based image analysis and extracellular vesicles in regenerative medicine.

As we continue to explore the limitless potential of AI in biotechnology, it's essential to stay connected and engaged with the latest developments in the field. Feel free to share your thoughts and questions in the comments section, and let's keep the conversation going.

If you haven't already, we encourage you to invite your friends, colleagues, and industry peers to subscribe to our bi-weekly newsletter and be part of this exciting journey.??

Inside AI Newsletter Team ????

Thanks for reading this article! Let us know in the comments below what you think about this topic, and be sure to subscribe to our biweekly Inside AI in Life Sciences newsletter, to get the latest tips, tricks, and news. Also, follow us here on LinkedIn .